The Globe and Mail reports in its Friday, Feb. 23, edition that RBC Capital analyst Douglas Miehm continues to rank Bausch Health Companies "sector perform." The Globe's David Leeder writes that Mr. Miehm boosted his share target by a buck to $9 (all figures U.S. unless otherwise stated). Analysts on average target the shares at $9.50. Mr. Miehm says in a note: "With Q4 results that were ahead of expectations and a strong 2024 guide complete, we expect investor focus to return to the important appellate court decision on Norwich/Xifaxan, which should be rendered between March and May, 2024. While we await the decision, we revise our estimates to incorporate the 2024 guide and update our valuation to reflect Bausch + Lomb revisions with our price target increased." The Globe reported on Feb. 2, 2022, and Aug. 12, 2022, that Mr. Miehm rated Bausch Health "outperform." It was then worth $31.83 (Canadian) and $7.92 (Canadian). The Globe reported on Sept. 2, 2022, that Mr. Miehm had cut his recommendation for Bausch Health to "sector perform." The shares could then be had for $8.67 (Canadian). The Globe reported on May 6, 2023, that Mr. Miehm was sticking with his "sector perform" call. It was then worth $8 (Canadian).